You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
RTX maintained its current-year outlook and expects top-line, bottom-line and free cash flow growth in 2027, citing strong demand and a $340 billion backlog.
RTX reported $2.6 billion of organic net sales growth and an $0.8 billion increase in operating profit for the quarter ended September 30, 2026, aided by $0.4 billion of tariff refunds.
RTX raised its full-year adjusted sales outlook to $97 to $97.5 billion, adjusted EPS to $7.65 to $7.75 and free cash flow to between nine and 9.2 billion. It ended Q3 with a record backlog of $340 billion, up 36% year-over-year.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. RTX delivered 11% Q3 sales growth and 33% adjusted EPS growth, expanded segment margins, built a record $340 billion backlog, and raised its full-year 2026 sales, EPS and free-cash-flow outlooks. Quarterly free cash flow fell 47%, while Pratt's customer-bankruptcy charge and OE weakness, expected Collins margin pressure, munitions supply-chain constraints, and defense-budget risk were the main offsets.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
A Q2-print read on SpaceX as a public company: how $15.8B of the $18.4B Q2 capex flowed into the AI segment, why Customer B at 19.5% and Customer A at 18.3% of revenue sit between the $47.5B backlog and the $100B December ARR target, and how the Cursor close reframes the same concentration risk.
Rocket Lab's record Q1 and $2.2B backlog show the bull case no longer rests on Neutron alone. The proposed Iridium merger could add a recurring-services engine, while financing, dilution and execution remain the price of that upside.
Rocket Lab enters Q2 2026 with record backlog of $2,219.8M and guided revenue of $225.0M–$240.0M, yet the stock trades at -55.2% from its $150.23 high on a $39.0B market cap against $679.6M of trailing revenue — a gap the equity-funded growth model and the un-flown Neutron debut have to close.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Company-funded Research and Development | $726M | Quarter Ended June 30, 2026 filing | — |
| Customer-funded Research and Development | $1.28B | Quarter Ended June 30, 2026 filing | — |
| Organic change in Cost of sales non-GAAP | $2.72B | Quarter Ended June 30, 2026 filing | — |
| Organic change in Net sales non-GAAP | $3.51B | Quarter Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RTX
this stock
RTX Corp
|
$267.97B | +8.3% | +17.1% | 32.2 | 1.0% |
|
SPCX
Space Exploration Technologies Corp
|
$1.89T | — | — | — | 1.0% |
|
GE
General Electric Co
|
$342.88B | +7.7% | +18.5% | 38.3 | 1.2% |
|
EADSF
Airbus SE
|
$178.35B | -3.2% | — | — | 0.1% |
|
LMT
Lockheed Martin Corp
|
$137.69B | +23.2% | +5.6% | 21.2 | 1.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
RTX maintained its current-year outlook and expects top-line, bottom-line and free cash flow growth in 2027, citing strong demand and a $340 billion backlog.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RTX | +4.8% | +2.4% | +11.0% | -0.6% | +8.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.2% | +3.6% | +10.5% | -0.4% | -2.3% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
